Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s M’s Science To Test Herpes Virus For Treating Cancers

This article was originally published in PharmAsia News

Executive Summary

M's Science, a Japanese biotechnology startup, expects to begin U.S. clinical trials by the end of the year on its cancer treatment. The company is relying on a naturally occurring herpes simplex virus to target specific cancer cells in people who already have been infected with the virus. M's Science is testing its treatment on head and neck cancers and expects to begin Phase II trials in 2010. Positive results there could lead the firm to expand the treatment's scope to other cancers. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts